Drug Trial Radar · NCT01437254
To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer
Last checked: Nov 19, 2026Latest source record: Nov 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Oct 2011
Primary completion
Apr 2012
Study completion Jan 2015
Sponsor
- Lead sponsor
- AHS Cancer Control AlbertaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Natural Resources, Canada; Edmonton PET Centre
- First posted
- Sep 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The cyclotron production model of Tc-99m pertechnetate (CPERT) has received significant validation in the independent expert review conducted by Natural Resources Canada (NRCan) in the follow up to the Chalk River crisis. The University of Alberta's Edmonton PET Centre and the Edmonton Radiopharmaceutical Centre is a cyclotron / radiopharmacy unit, providing a safe, cost effective, unsubsidized, and reliable supply of radiopharmaceuticals to hospitals and clinics in Edmonton and northern Alberta. A Phase I study is proposed to show safety of CPERT as well as comparability with generator-produced Tc-99m pertechnetate (GPERT) in subjects with well differentiated thyroid carcinoma post-thyroidectomy and prior to planned I-131 Iodide treatment.
Conditions
- Thyroid Neoplasms
Interventions
CPERTDrug
Single 340 MBq CPERT scan in first 10 subjects
GPERTDrug
Single 340 MBq GPERT scan in up to 20 case-matched controls
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of CPERTTime frame: 7 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cross Cancer Institute
Edmonton, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.